That is misleading. It is not an 18% reduction. It is an 18% reduction vs the placebo. They are currently already on the current standard of care, and this is outperforming that. If a drug outperforms standard of care, that is a very positive result!
- Forums
- ASX - By Stock
- Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
That is misleading. It is not an 18% reduction. It is an 18%...
-
- There are more pages in this discussion • 595 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
45.5¢ |
Change
0.015(3.41%) |
Mkt cap ! $247.7M |
Open | High | Low | Value | Volume |
43.5¢ | 45.5¢ | 43.5¢ | $226.4K | 503.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 21610 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.5¢ | 35271 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 59099 | 0.450 |
7 | 165490 | 0.445 |
6 | 75318 | 0.440 |
6 | 382470 | 0.435 |
7 | 97485 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.455 | 95586 | 5 |
0.460 | 153278 | 11 |
0.465 | 178181 | 9 |
0.470 | 83619 | 7 |
0.475 | 181871 | 6 |
Last trade - 10.51am 15/08/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online